Evidence map›Paper›PMID 36851087›Full record

ReviewVaccines2023

Can COVID-19 Vaccines Induce Premature Non-Communicable Diseases: Where Are We Heading to?

Altijana Hromić-Jahjefendić, Debmalya Barh, Vladimir Uversky, Alaa A Aljabali, Murtaza M Tambuwala, Khalid J Alzahrani, Fuad M Alzahrani, Saleh Alshammeri, Kenneth Lundstrom

Open access · goldAbstract readReview
In one paragraph

Review in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. COVID-19 and cardiovascular disease in patients with chronic kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024
    Review
  8. Observational
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 7 countries.

Altijana Hromić-JahjefendićDepartment of Genetics and Bioengineering, Faculty of Engineering and Natural Sciences, International University of Sarajevo, Hrasnicka Cesta 15, 71000 Sarajevo, Bosnia and Herzegovina.
Debmalya BarhDepartment of Genetics, Ecology and Evolution, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte 31270-901, Brazil.ORCID 0000-0002-2557-7768
Vladimir UverskyDepartment of Molecular Medicine and USF Health Byrd Alzheimer's Institute, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.ORCID 0000-0002-4037-5857
Alaa A AljabaliDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Yarmouk University, P.O. Box 566, Irbid 21163, Jordan.ORCID 0000-0002-9519-6338
Murtaza M TambuwalaLincoln Medical School, Brayford Pool Campus, University of Lincoln, Lincoln LN6 7TS, UK.ORCID 0000-0001-8499-9891
Khalid J AlzahraniDepartment of Clinical Laboratories Sciences, College of Applied Medical Sciences, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia.ORCID 0000-0002-6688-0106
Fuad M AlzahraniDepartment of Clinical Laboratories Sciences, College of Applied Medical Sciences, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia.ORCID 0000-0001-6930-5214
Saleh AlshammeriDepartment of Optometry, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia.ORCID 0000-0002-0179-0767
Kenneth LundstromPanTherapeutics, Route de Lavaux 49, CH1095 Lutry, Switzerland.
Taif University · SAInternational University of Sarajevo · BAQassim University · SAUniversidade Federal de Minas Gerais · BRUniversity of Lincoln · GBUniversity of South Florida · USYarmouk University · JO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

According to the WHO, as of January 2023, more than 850 million cases and over 6.6 million deaths from COVID-19 have been reported worldwide. Currently, the death rate has been reduced due to the decreased pathogenicity of new SARS-CoV-2 variants, but the major factor in the reduced death rates is the administration of more than 12.8 billion vaccine doses globally. While the COVID-19 vaccines are saving lives, serious side effects have been reported after vaccinations for several premature non-communicable diseases (NCDs). However, the reported adverse events are low in number. The scientific community must investigate the entire spectrum of COVID-19-vaccine-induced complications so that necessary safety measures can be taken, and current vaccines can be re-engineered to avoid or minimize their side effects. We describe in depth severe adverse events for premature metabolic, mental, and neurological disorders; cardiovascular, renal, and autoimmune diseases, and reproductive health issues detected after COVID-19 vaccinations and whether these are causal or incidental. In any case, it has become clear that the benefits of vaccinations outweigh the risks by a large margin. However, pre-existing conditions in vaccinated individuals need to be taken into account in the prevention and treatment of adverse events.

Indexed as

COVID-19 vaccinespremature NCDsSARS-CoV-2vaccine hesitancy

Identifiers

PMID36851087
PMCPMC9960675
OpenAlexW4317393614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.